Atrial Fibrillation with Rapid Ventricular Response

Introduction to AFib with RVR

Atrial fibrillation with rapid ventricular response (AFib with RVR) may precipitate tachycardia-induced cardiomyopathy with prolonged rapid rates, particularly in patients with pre-existing cardiac dysfunction 1

In patients with Wolff-Parkinson-White (WPW) Syndrome, the European Society of Cardiology recommends avoiding AV nodal blocking agents (beta blockers, calcium channel blockers, digoxin) as they can increase conduction through the accessory pathway and precipitate ventricular fibrillation 2, 3
For patients with WPW Syndrome, the European Society of Cardiology suggests using procainamide or ibutilide instead 3
In cases of thyrotoxicosis, the European Society of Cardiology recommends beta blockers as first-line therapy for rate control, and non-dihydropyridine calcium channel blockers if beta blockers are contraindicated 3

The American College of Cardiology recommends using beta blockers cautiously in patients with heart failure, and amiodarone may be preferred for acute rate control 4
Beta blockers remain first-line therapy for AF rate control in HFpEF, but require careful dose titration, according to the American College of Cardiology 5, 6
The European Society of Cardiology suggests considering combination therapy with reduced-dose beta blocker plus digoxin for controlling resting heart rate, particularly in symptomatic patients 7
Non-dihydropyridine calcium channel blockers, such as diltiazem and verapamil, are recommended first-line options for HFpEF patients, but should be used with caution due to potential negative inotropic effects 6, 7
Initial resting heart rate target should be <110 bpm, rather than strict control, as recommended by the European Heart Rhythm Association 7
The following medication dosages are recommended for rate control:

Medication	Dosage
Metoprolol	2.5-5 mg IV bolus over 2 minutes, up to 3 doses, or 25-100 mg orally twice daily
Esmolol	500 μg/kg IV over 1 minute, then 50-300 μg/kg/min
Diltiazem	0.25 mg/kg IV over 2 minutes, then 5-15 mg/h, or 40-120 mg orally three times daily
Verapamil	0.075-0.15 mg/kg IV over 2 minutes, or 40-120 mg orally three times daily
Digoxin	0.25 mg IV every 2 hours, up to 1.5 mg, or 25-100 mg orally twice daily
Amiodarone	150 mg IV over 10 minutes, then 0.5-1 mg/min	[4, 8]

The American College of Cardiology recommends considering electrical or pharmacological cardioversion in symptomatic patients with persistent atrial fibrillation, with anticoagulation performed for at least 3-4 weeks if the atrial fibrillation has a duration >48 hours or is of unknown duration 9, 10
Pharmacological options for cardioversion include amiodarone, flecainide (only in the absence of structural heart disease), propafenone (only in the absence of structural heart disease), and ibutilide 10, 2, 11
Electrical cardioversion is recommended for patients with hemodynamic instability, while pharmacological cardioversion with ibutilide or amiodarone is recommended for hemodynamically stable patients (Class IIa, Level of Evidence A) 11, 10, 3
The American College of Cardiology recommends oral anticoagulation as mandatory in patients with persistent atrial fibrillation to prevent thromboembolic events, with direct oral anticoagulants (DOACs) preferred over vitamin K antagonists 9, 10
Anticoagulation should be maintained regardless of the chosen strategy (rhythm or rate control) 10
The CHA₂DS₂-VASc score should be calculated to assess stroke risk, and anticoagulation with warfarin (INR 2.0-3.0) is recommended for at least 3 weeks before and 4 weeks after cardioversion for patients with atrial flutter of ≥48 hours or unknown duration 11, 9

AV node ablation with pacemaker implantation may be considered if pharmacological management fails and bradycardia persists despite adequate rate control attempts, as recommended by the Heart Rhythm Society 6
The European Society of Cardiology recommends considering catheter ablation in patients with recurrence of atrial fibrillation after initial ablation with pulmonary vein isolation, with oral anticoagulation maintained uninterrupted during the ablation procedure 9
After acute rate control is achieved, evaluate for tachycardia-induced cardiomyopathy, and optimize heart failure therapy with ACE inhibitors/ARBs, beta-blockers, mineralocorticoid receptor antagonists, and diuretics as needed, according to standard heart failure management guidelines 12, 13, 14, 9, 7
Uncontrolled heart rate can lead to deterioration of ventricular function, heart failure, and increased mortality, but tachycardia-induced cardiomyopathy typically resolves within 6 months of adequate rate or rhythm control 8, 15, 16